The Korean Journal of Medicine

  • 제86권2호
  • /
  • Pages.142-151
  • /
  • 2014
  • /
  • 1738-9364(pISSN)
  • /
  • 2289-0769(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

신장이식

Kidney Transplantation

  • 김찬덕 (경북대학교 의학전문대학원 내과학교실 신장내과)
  • Kim, Chan-Duck (Division of Nephrology, Department of Internal Medicine, Kyungpook National University School of Medicine)
  • 발행 : 2014.02.01
⟨ 이전 논문 다음 논문 ⟩

초록

Kidney transplantation is the treatment of choice for end stage renal disease. Successful kidney transplantation improves the quality of life and reduces the mortality risk for most patients, when compared with maintenance dialysis. Recent advances, including immunosuppressants, desensitization treatment for highly sensitized kidney transplant candidates, and better medical care, have resulted in an increase number of transplants with improved outcomes. However, kidney transplant recipients require close follow-up after transplantation since they are on complex immunosuppressive regimens that render them susceptible to infection, malignancy, and cardiovascular disease. The additional obstacles of kidney transplantation include the lack of improvement in long term outcomes, shortage of organs, and multiple co-morbidities due to their underlying chronic kidney disease. To improve the long-term outcome of renal allograft, physicians must be aware in developing newer immunosuppressive regimens, with lower side effects, and reduction of death with functioning graft and chronic allograft dysfunction will be the greatest challenge of all physicians who care for kidney transplant recipients. This review highlights current status of kidney transplantation in Korea, brief transplant immunology, immunologic tests, donor/recipient evaluation, immunosuppressive medications, and complications of kidney transplantation involving rejection, post transplantation infections, malignancy, cardiovascular disease and recurrence of primary disease.

키워드

참고문헌

  1. Suthanthiran M, Strom TB. Renal transplantation. N Engl J Med 1994;331:365-376. https://doi.org/10.1056/NEJM199408113310606
  2. Schnuelle P, Lorenz D, Trede M, Van Der Woude FJ. Impact of renal cadaveric transplantation on survival in end-stage renal failure: evidence for reduced mortality risk compared with hemodialysis during long-term follow-up. J Am Soc Nephrol 1998;9:2135-2141.
  3. Korean Network for Organ Sharing (KONOS). Annual report of the transplant 2012 [Internet]. Seoul (KR): Korean Network for Organ Sharing, c2013 [cited 2013 Dec 22]. Available from: http://www.konos.go.kr.
  4. Matas AJ, Smith JM, Skeans MA, et al. OPTN/SRTR 2011 Annual Data Report: kidney. Am J Transplant 2013;13(Suppl 1):11-46.
  5. ESRD Registry Committee, Korean Society of Nephrology. Current Renal Replacement Therapy in Korea. Proceedings of the 33rd Annual Autumn Meeting of the Korean Society of Nephrology 2013:7-35.
  6. Ibrahim HN, Foley R, Tan L, et al. Long-term consequences of kidney donation. N Engl J Med 2009;360:459-469. https://doi.org/10.1056/NEJMoa0804883
  7. Fehrman-Ekholm I, Duner F, Brink B, Tyden G, Elinder CG. No evidence of accelerated loss of kidney function in living kidney donors: results from a cross-sectional follow-up. Transplantation 2001;72:444-449. https://doi.org/10.1097/00007890-200108150-00015
  8. Hernandez-Fuentes MP, Warrens AN, Lechler RI. Immunologic monitoring. Immunol Rev 2003;196:247-264. https://doi.org/10.1046/j.1600-065X.2003.00092.x
  9. El-Awar N, Lee J, Terasaki PI. HLA antibody identification with single antigen beads compared to conventional methods. Hum Immunol 2005;66:989-997. https://doi.org/10.1016/j.humimm.2005.07.005
  10. Kong JM, Lee LD, Jeong JH, et al. ABO blood group incompatible living donor kidney transplantation without splenectomy. J Korean Soc Transplant 2009;23:71-76.
  11. Egawa H, Tanabe K, Fukushima N, Date H, Sugitani A, Haga H. Current status of organ transplantation in Japan. Am J Transplant 2012;12:523-530. https://doi.org/10.1111/j.1600-6143.2011.03822.x
  12. Montgomery RA, Lonze BE, King KE, et al. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 2011;365:318-326. https://doi.org/10.1056/NEJMoa1012376
  13. Huh KH, Kim BS, Yang J, et al. Kidney transplantation after desensitization in sensitized patients: a Korean National Audit. Int Urol Nephrol 2012;44:1549-1557. https://doi.org/10.1007/s11255-012-0169-1
  14. Jin MK, Cho JH, Kwon O, et al. Successful kidney transplantation after desensitization using plasmapheresis, low-dose intravenous immunoglobulin, and rituximab in highly sensitized patients: a single-center experience. Transplant Proc 2012;44:200-203. https://doi.org/10.1016/j.transproceed.2011.11.040
  15. Denton MD, Magee CC, Sayegh MH. Immunosuppressive strategies in transplantation. Lancet 1999;353:1083-1091. https://doi.org/10.1016/S0140-6736(98)07493-5
  16. Webster AC, Playford EG, Higgins G, Chapman JR, Craig JC. Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation 2004;77:166-176. https://doi.org/10.1097/01.TP.0000109643.32659.C4
  17. Morton RL, Howard K, Webster AC, Wong G, Craig JC. The cost-effectiveness of induction immunosuppression in kidney transplantation. Nephrol Dial Transplant 2009;24:2258-2269. https://doi.org/10.1093/ndt/gfp174
  18. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007;357:2562-2575. https://doi.org/10.1056/NEJMoa067411
  19. Chapman JR. Chronic calcineurin inhibitor nephrotoxicity-lest we forget. Am J Transplant 2011;11:693-697. https://doi.org/10.1111/j.1600-6143.2011.03504.x
  20. Pascual J. Steroid avoidance or withdrawal in kidney transplantation. Curr Opin Organ Transplant 2011;16:600-605. https://doi.org/10.1097/MOT.0b013e32834c23fa
  21. Sis B, Mengel M, Haas M, et al. Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010;10:464-471. https://doi.org/10.1111/j.1600-6143.2009.02987.x
  22. Cohen D, Colvin RB, Daha MR, et al. Pros and cons for C4d as a biomarker. Kidney Int 2012;81:628-639. https://doi.org/10.1038/ki.2011.497
  23. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009;9(Suppl 3):S1-155.
  24. Roberts DM, Jiang SH, Chadban SJ. The treatment of acute antibody-mediated rejection in kidney transplant recipients-a systematic review. Transplantation 2012;94:775-783.
  25. Solez K, Colvin RB, Racusen LC, et al. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007;7:518-526. https://doi.org/10.1111/j.1600-6143.2006.01688.x
  26. Billing H, Rieger S, Susal C, et al. IVIG and rituximab for treatment of chronic antibody-mediated rejection: a prospective study in paediatric renal transplantation with a 2-year followup. Transpl Int 2012;25:1165-1173. https://doi.org/10.1111/j.1432-2277.2012.01544.x
  27. Fehr T, Rusi B, Fischer A, Hopfer H, Wuthrich RP, Gaspert A. Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection. Transplantation 2009;87:1837-1841. https://doi.org/10.1097/TP.0b013e3181a6bac5
  28. The AST Infectious Diseases Community of Practice. The American Society of Transplantation Infectious Disease Guidelines 3rd Edition. Am J Transplant 2013;13(Suppl 4):S1-371.
  29. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007;370:59-67. https://doi.org/10.1016/S0140-6736(07)61050-2
  30. Vajdic CM, McDonald SP, McCredie MR, et al. Cancer incidence before and after kidney transplantation. JAMA 2006;296:2823-2831. https://doi.org/10.1001/jama.296.23.2823
  31. Ju MK, Joo DJ, Kim SJ, et al. Chronologically different incidences of post-transplant malignancies in renal transplant recipients: single center experience. Transpl Int 2009;22:644-653. https://doi.org/10.1111/j.1432-2277.2009.00846.x
  32. Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005;352:1317-1323. https://doi.org/10.1056/NEJMoa042831
  33. Ojo AO. Cardiovascular complications after renal transplantation and their prevention. Transplantation 2006;82:603-611.
  34. Kasiske B, Cosio FG, Beto J, et al. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant 2004;4(Suppl 7):13-53.
  35. Kidney Disease Improving Global Outcomes (KDIGO) Lipid Guideline Development Work Group. KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney Int Suppl 2013;3:284-285. https://doi.org/10.1038/kisup.2013.37
  36. Ponticelli C, Glassock RJ. Posttransplant recurrence of primary glomerulonephritis. Clin J Am Soc Nephrol 2010;5:2363-2372. https://doi.org/10.2215/CJN.06720810
  37. Sprangers B, Kuypers DR. Recurrence of glomerulonephritis after renal transplantation. Transplant Rev (Orlando) 2013;27:126-134. https://doi.org/10.1016/j.trre.2013.07.004

피인용 문헌

  1. Quality of Life among End-stage Renal Disease Treatments and Economic Evaluation of Renal Transplantation and Hemodialysis Treatments vol.29, pp.4, 2014, https://doi.org/10.4285/jkstn.2015.29.4.200
  2. 신장이식환자의 자가간호이행 영향 요인 및 경과기간별 이행정도 vol.15, pp.3, 2017, https://doi.org/10.14400/jdc.2017.15.3.259
  3. Chest Pain in a Renal Transplant Recipient due to Concomitant Cytomegalovirus and Herpes Simplex Virus Esophagitis vol.19, pp.1, 2019, https://doi.org/10.7704/kjhugr.2019.19.1.61
  4. Factors affecting mortality during the waiting time for kidney transplantation: A nationwide population-based cohort study using the Korean Network for Organ Sharing (KONOS) database vol.14, pp.4, 2014, https://doi.org/10.1371/journal.pone.0212748
  5. Family Characteristics, Family Support, Family Function and Compliance of Patient Role Behavior in Long-term Hemodialysis Patients vol.22, pp.1, 2014, https://doi.org/10.7587/kjrehn.2019.58